Gene Therapies for Sickle Cell Disease

Area of Science:

• Hematology
• Gene Therapy
• Genetics

Background:

• Sickle cell disease (SCD) is a common, inherited blood disorder impacting millions globally, particularly those of African ancestry.
• SCD causes severe pain, organ damage, and reduced quality of life, with current treatments managing symptoms but not the underlying genetic cause.
• Allogeneic hematopoietic stem cell transplant (HSCT) offers a cure but faces limitations in donor availability and safety.

Purpose of the Study:

• To review the efficacy and safety of exagamglogene autotemcel and lovotibeglogene autotemcel for SCD management.
• To evaluate the therapeutic potential, cost, and accessibility of these gene therapies in clinical practice.

Main Methods:

• Literature search of PubMed and Medline databases from 2017 to 2024.
• Focused on primary research concerning exagamglogene autotemcel and lovotibeglogene autotemcel.

Main Results:

• Relevant studies were identified and data on the two gene therapies were summarized.
• The review synthesized information on the performance and safety profiles of these novel treatments.

Conclusions:

• Exagamglogene autotemcel and lovotibeglogene autotemcel represent significant advancements in SCD management.
• These gene therapies address the genetic basis of SCD, offering potential cures for affected patients.